The 2- and 3-year OS rates were 48% and 41%, respectively.14 In a recently presented phase 3 studies in patients with advanced melanoma after prior anti-CTLA4 therapy, the objective response rate was also 32% in patients treated with nivolumab comparing to 11% in the chemotherapy arm. The gene discussed is CTLA4; the disease is melanoma.